作者
Thomas M MacDonald, Chris J Hawkey, Ian Ford, John JV McMurray, James M Scheiman, Jesper Hallas, Evelyn Findlay, Diederick E Grobbee, FD Richard Hobbs, Stuart H Ralston, David M Reid, Matthew R Walters, John Webster, Frank Ruschitzka, Lewis D Ritchie, Susana Perez-Gutthann, Eugene Connolly, Nicola Greenlaw, Adam Wilson, Li Wei, Isla S Mackenzie
发表日期
2017/6/14
期刊
European heart journal
卷号
38
期号
23
页码范围
1843-1850
出版商
Oxford University Press
简介
Background
Selective cyclooxygenase-2 inhibitors and conventional non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) have been associated with adverse cardiovascular (CV) effects. We compared the CV safety of switching to celecoxib vs. continuing nsNSAID therapy in a European setting.
Method
Patients aged 60 years and over with osteoarthritis or rheumatoid arthritis, free from established CV disease and taking chronic prescribed nsNSAIDs, were randomized to switch to celecoxib or to continue their previous nsNSAID. The primary endpoint was hospitalization for non-fatal myocardial infarction or other biomarker positive acute coronary syndrome, non-fatal stroke or CV death analysed using a Cox model with a pre-specified non-inferiority limit of 1.4 for the hazard ratio (HR).
Results
In total, 7297 participants were randomized. During a …
学术搜索中的文章
TM MacDonald, CJ Hawkey, I Ford, JJV McMurray… - European heart journal, 2017